Assignee
BYONDIS BV
NL17 patents
Top patents by PatentIndex Score
US11104968B2Aug 31, 2021
Site-specific conjugation of linker drugs to antibodies and resulting ADCS
BYONDIS BV2 citations71
US10814009B2Oct 27, 2020
Selective reduction of cysteine-engineered antibodies
BYONDIS BV4 citations71
US11584801B2Feb 21, 2023
Anti-5T4 antibodies and antibody-drug conjugates
BYONDIS BV2 citations66
US11008400B2May 18, 2021
Anti-5T4 antibodies and antibody-drug conjugates
BYONDIS BV5 citations66
US12350345B2Jul 8, 2025
Dual conjugation process for preparing antibody-drug conjugates
BYONDIS BV0 citations61
US11696958B2Jul 11, 2023
Dual conjugation process for preparing antibody-drug conjugates
BYONDIS BV0 citations61
US12180552B2Dec 31, 2024
Site-specific conjugation of linker drugs to antibodies and resulting ADCs
BYONDIS BV0 citations60
US11419944B2Aug 23, 2022
Non-linear self-immolative linkers and conjugates thereof
BYONDIS BV0 citations59
US11382982B2Jul 12, 2022
Duocarmycin ADCs showing improved in vivo antitumor activity
BYONDIS BV0 citations58
US12180295B2Dec 31, 2024
Humanized anti-SIRPα antibodies
BYONDIS BV0 citations57
US11718681B2Aug 8, 2023
Anti-SIRP α antibodies
BYONDIS BV0 citations51
US11633492B2Apr 25, 2023
Process for the synthesis of linker-drug vc-seco-DUBA
BYONDIS BV0 citations51
US11274159B2Mar 15, 2022
Anti-SIRPα antibodies
BYONDIS BV1 citations51
US11077204B2Aug 3, 2021
Compositions comprising antibody-duocarmycin drug conjugates
BYONDIS BV0 citations43
US10815194B2Oct 27, 2020
Process for the preparation of mono-protected α,ω-diamino alkanes
BYONDIS BV0 citations35
US10821191B2Nov 3, 2020
SYD985 treatment of T-DM1 refractory cancer patients
BYONDIS BV0 citations32
US12178881B2Dec 31, 2024
Filterable duocarmycin-containing antibody-drug conjugate compositions and related methods
BYONDIS BV0 citations31